Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~* Subject had successfully completed either Protocol Fx-006 or Fx-1A-201.~* Male or female subjects with ATTR-PN who had not undergone liver or heart transplantation at time of enrollment.~* If female, subject was post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control~Key Exclusion criteria:~* Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs)~* Pregnant or breast feeding female subjects.~* Clinically significant medical condition that, in the opinion of the investigator, would place the subject at an increased risk to participate in the study.~* An alanine aminotransferase (ALT) and aspartate aminotransferase (AST) value \>3 × upper limit of normal (ULN) that, in the medical judgment of the investigator, was due to reduced liver function or active liver disease.~* Sexually active males with partners of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 3 months after last dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).